Exagen Inc. anticipates $65M revenue for 2025 amid ASP growth and new biomarker launches
Source: SeekingAlpha
2025-05-05 16:52:35 ET
More on Exagen
- Exagen Inc. (XGN) Q1 2025 Earnings Call Transcript
- Exagen: Buy An Undervalued Diagnostics Developer That Is On The Path To Profitability
- Exagen Inc. (XGN) Q4 2024 Earnings Call Transcript
- Exagen announces senior secured credit facility
- Seeking Alpha’s Quant Rating on Exagen
Read the full article on Seeking Alpha
For further details see:
Exagen Inc. anticipates $65M revenue for 2025 amid ASP growth and new biomarker launches
Exagen Inc.
NASDAQ: XGN
XGN Trading
1.96% G/L:
$3.125 Last:
90,126 Volume:
$3.07 Open:
XGN Latest News
February 24, 2026 09:00:00 am
Exagen Inc. to Announce Fourth Quarter and Full Year 2025 Financial Results on March 10, 2026
XGN Stock Data
$80,000,739
13,869,817
3.15%
15
N/A
Medical Diagnostics & Screening
Healthcare
US
Vista
